| 1.62 0.02 (1.25%) | 05-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.34  |
1-year : | 2.68 |
| Resists | First : | 2 |
Second : | 2.29 |
| Pivot price | 1.67 |
|||
| Supports | First : | 1.52 | Second : | 1.26 |
| MAs | MA(5) : | 1.62 |
MA(20) : | 1.74 |
| MA(100) : | 2.31 |
MA(250) : | 4.08 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 19.7 |
| RSI | RSI(14): 37.1 |
|||
| 52-week | High : | 9.76 | Low : | 1.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CARM ] has closed above bottom band by 28.0%. Bollinger Bands are 56.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.67 - 1.68 | 1.68 - 1.69 |
| Low: | 1.57 - 1.58 | 1.58 - 1.59 |
| Close: | 1.61 - 1.62 | 1.62 - 1.63 |
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Fri, 03 May 2024
Carisma Therapeutics (NASDAQ:CARM) Shares Down 1.8% - MarketBeat
Fri, 03 May 2024
Carisma Therapeutics (NASDAQ:CARM) Stock Price Down 1.8% - Defense World
Thu, 02 May 2024
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Thu, 02 May 2024
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer - PR Newswire
Mon, 29 Apr 2024
Carisma Therapeutics to Present Groundbreaking Cancer Study at ASCO 2024 - MyChesCo
Wed, 24 Apr 2024
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 ... - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 28.6 (%) |
| Held by Institutions | 40.8 (%) |
| Shares Short | 1,580 (K) |
| Shares Short P.Month | 2,080 (K) |
| EPS | -2.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.64 |
| Profit Margin | 0 % |
| Operating Margin | -602.8 % |
| Return on Assets (ttm) | -68.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 15 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.35 |
| EBITDA (p.s.) | -2.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | 2.49 |
| Price to Sales | 4.51 |
| Price to Cash Flow | -0.83 |
| Dividend | 0.36 |
| Forward Dividend | 0 |
| Dividend Yield | 22.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|